# Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

> **NCT01560624** · PHASE3 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 690 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Treprostinil Diolamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01560624
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-26
- **Primary completion:** 2018-06-24
- **Final completion:** 2018-06-24
- **Target enrollment:** 690 (ACTUAL)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01560624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01560624, "Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01560624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*